Acceleron  

News

  • Event
    Dec 23, 2011
    Acceleron Secures $30M Private Financing
    + VIEW FULL Event
  • Event
    Nov 28, 2011
    Acceleron Pharma to Present at Two Upcoming Investor Conferences
    + VIEW FULL Event
  • Press Release
    Sep 13, 2011
    Acceleron Initiates Phase 1 Study of ACE-536
    + VIEW FULL Press Release
  • Event
    Sep 12, 2011
    Acceleron Pharma to Present at Two September Investor Conferences
    + VIEW FULL Event
  • In the News
    Aug 5, 2011
    Xconomy: Acceleron, Celgene Take Aim at Amgen’s Multi-Billion Dollar Anemia Market
    + VIEW FULL In the News
  • In the News
    Aug 4, 2011
    BioWorld Today: New Acceleron, Celgene Deal Anything But ‘Anemic’
    + VIEW FULL In the News
  • Press Release
    Aug 3, 2011
    Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program
    + VIEW FULL Press Release
  • In the News
    Aug 3, 2011
    Scrip Intelligence: Celgene Pays Acceleron $25M Upfront Under Anemia Drug Partnership
    + VIEW FULL In the News
  • Publication
    Jun 30, 2011
    ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011; 117(26): 6999-7006
    + VIEW FULL Publication
  • Press Release
    Jun 2, 2011
    Celgene and Acceleron Initiate Phase 2/3 Study of ACE-011 (sotatercept) to Treat Chemotherapy-Induced Anemia in Patients with Lung Cancer
    + VIEW FULL Press Release
  • Event
    May 9, 2011
    Acceleron Pharma Presents Anabolic Bone Effects of ACE-661 at International Scientific Meeting
    + VIEW FULL Event
  • Publication
    May 1, 2011
    Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse. Muscle & Nerve 2011; 43(5): 694-9
    + VIEW FULL Publication
  • Event
    Apr 5, 2011
    Acceleron Presents Positive Results from Phase 1 Study of ACE-041 in Patients with Advanced Cancer
    + VIEW FULL Event
  • Event
    Mar 30, 2011
    Acceleron Pharma to Present at Two Upcoming Investor Conferences in April
    + VIEW FULL Event
  • Publication
    Mar 1, 2011
    Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol 2011;178(3):1287-97
    + VIEW FULL Publication
  • Publication
    Dec 1, 2010
    Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J. Bone Miner Res 2010; 25(12): 2633-46
    + VIEW FULL Publication
  • Press Release
    Nov 29, 2010
    Acceleron Appoints Kevin F. McLaughlin as Senior Vice President and Chief Financial Officer
    + VIEW FULL Press Release
  • Event
    Nov 19, 2010
    Acceleron Announces Interim Findings from the ACE-041 Phase 1, First-in-Human Clinical Trial at 22nd EORTC-NCI-AACR Symposium
    + VIEW FULL Event
  • Press Release
    Nov 19, 2010
    Acceleron Announces Departure of Jasbir Seehra, Ph.D. Chief Scientific Officer
    + VIEW FULL Press Release
  • Press Release
    Nov 2, 2010
    Acceleron Awarded Grants from the Qualifying Therapeutic Discovery Project Program
    + VIEW FULL Press Release
  • Event
    Oct 13, 2010
    Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
    + VIEW FULL Event
  • Publication
    Oct 1, 2010
    Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010;12(5):586-97
    + VIEW FULL Publication
  • In the News
    Sep 15, 2010
    FierceBiotech Names Acceleron Pharma as One of the “Fierce 15” of 2010
    + VIEW FULL In the News
  • Press Release
    Sep 9, 2010
    Acceleron Pharma Announces Joint Development and Commercialization Agreement with Shire on Novel Muscle Therapeutics for Orphan Diseases
    + VIEW FULL Press Release
  • Publication
    Sep 1, 2010
    A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. Endocrinology 2010; 151(9): 4289–4300
    + VIEW FULL Publication